The Uromigos

Episode 181: Relapsed Germ Cell Tumours 27.06.2022 27:30 ↓

Darren Feldman describes different approaches and the TIGER study. 

Episode 180: Enzalutamide vs active surveillance in early prostate cancer 20.06.2022 27:34 ↓

Neil Shore describes his recent controversial paper. 

Episode 179: PSMA PET for Lutetium-177 in prostate cancer 20.06.2022 32:13 ↓

Phillip Kuo discusses the biomarker to select patients for therapy. 

Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer 07.06.2022 20:27 ↓

Veda Giri gives an overview of her presentation at ASCO 2022. 

Episode 177: ASCO 2022: ENZAMET survival update 05.06.2022 20:07 ↓

Ian Davis describes the implications of the study. 

Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer 05.06.2022 19:36 ↓

Matt Galski discusses data from ASCO 2022. 

Episode 175: ASCO 2022: Targeting the microbiome in renal cancer 04.06.2022 20:12 ↓

Nazli Dizman describes her latest data on CBM588 in renal cancer. 

Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer 03.06.2022 24:39 ↓

Amir Goldkorn describes translational findings from a phase 2 bladder trial. 

Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer 03.06.2022 20:25 ↓

Rob Jones describes cabozantinib in urothelial cancer.

Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer 03.06.2022 20:20 ↓

Chris Ryan describes the results of this adjuvant study. 

Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects 23.05.2022 25:49 ↓

Jonathan Rosenberg gives an overview of the current landscape. 

Episode 170: APCCC Meeting Summary 16.05.2022 27:59 ↓

Silke Gillessen and Chris Sweeney summarise the meeting.

Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC 09.05.2022 24:01 ↓

Syed Hussein and Sam Funt describe their studies. 

Episode 168: Mechanisms of response to PD1 therapy in renal cancer 02.05.2022 30:49 ↓

David Braun gives an overview. 

Episode 167: Highlights from EIKCS oral session 22.04.2022 25:13 ↓

Michael Staehler gives an overview of the session. 

Episode 166: Prostate cancer debate: doublet vs triplet first line therapy 18.04.2022 33:22 ↓

Rana McKay and Kim Chi discuss this topic, with unexpected conclusions....

Episode 165: Paper of the Month - ENZAMET quality of life data 06.04.2022 27:49 ↓

Martin Stockler describes this paper, which shows mixed effects of enza on QOL in prostate cancer. 

Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer 01.04.2022 22:19 ↓

Yelena Janjigian describes ipi/nivo vs nivo chemo vs chemo in Gastric cancer - published in Nature

Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer 21.03.2022 34:00 ↓

David McDermott attempts to get his point across...again. 

Episode 162: Debate - Adjuvant nivolumab for bladder cancer 14.03.2022 20:07 ↓

Matt Galski and Tom Powles take the FDA and EMA approach respectively. 

Episode 161: Platinum eligibility in urothelial cancer 07.03.2022 23:44 ↓

Shilpa Gupta describes cisplatin and platinum eligibility. 

Episode 160: APCCC - PMSA PET as a diagnostic 28.02.2022 30:18 ↓

Stefano Fanti describes this topic. 

Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer 19.02.2022 21:08 ↓

Axel Bex discusses these topics. 

Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer 19.02.2022 25:56 ↓

Fred Saad describes the results of this trial. 

Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer 18.02.2022 20:49 ↓

Jonathan Rosenberg describes the results of this positive randomised trial.